More on AMGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $407.27 |
|
|||
| Open | $410.16 | ||||
| 52 Wk High | $176.85 | ||||
| 52 Wk Low | $133.64 | ||||
| Day High | $410.16 | ||||
| Day Low | $401.96 | ||||
| P/E | 60.85 | ||||
| EPS | $6.64 | ||||
| Volume | 1,285,366 | ||||
- Amgen (AMGN) PT Raised to $500 at Scotiabank
- Canaccord Reiterates Hold Rating on Amgen (AMGN)
- Amgen (AMGN) PT Raised to $410 at Jefferies
- Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)
- Amgen's dazodalibep meets primary endpoint in Sjögren's Phase 3 trial
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- Amgen (AMGN) PT Lowered to $430 at UBS
- FDA cuts monitoring time for Amgen's Imdelltra initial doses
- FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Entities mentioned with AMGN
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- Dividend | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
